"Extreme remedies are very appropriate for extreme diseases"---Hippocrates. This philosophy has been epitomized by the "bench to bedside" success story of enzyme replacement therapy (ERT) for lysosomal storage disorders (LSDs). LSDs are a group of rare inborn errors of metabolism which are progressive, devastating multisystem disorders impairing growth, vision, ambulation, cardiac, or pulmonary function, causing debilitating bone and joint disease and invariably attenuating life span.\[[@ref1]\] Each disorder is a result of a deficiency of any one of the 50 lysosomal enzymes, activator proteins, or membrane transport proteins.\[[@ref2]\] Incidence of LSDs in India is not known; however, it is 1 in 5000--8000 live births in the United States, Europe, and Australia.\[[@ref3]\] Globally, the most common LSDs with an incidence of 1 in 60,000--120,000 are Gaucher disease, Fabry disease, and mucopolysaccharidosis (MPS) type I.\[[@ref4]\]

Before 1990, treatment was palliative, although bone marrow transplant was performed for several LSDs since 1980s with variable results.\[[@ref5]\] Hope for treatment of LSDs became a reality with development of ERT. In the early 1970s, Brady *et al*., at the National Institute of Health, USA, were the first to successfully demonstrate clinical proof of efficacy of ERT by administration of purified human placental glucocerebrosidase intravenously in a 15-year-old and a 51-year-old patient with Gaucher disease.\[[@ref6]\] This placenta-derived product was the first ERT to be marketed in 1991 as alglucerase.

Currently, ERT is manufactured using the DNA recombinant technology and is available commercially for 10 LSDs \[[Table 1](#T1){ref-type="table"}\].\[[@ref7][@ref8]\] This rapid stride is because of (i) the Orphan Drugs Act of 1983 in the United States, which provided pharmaceutical companies economic incentives to develop therapeutic products for rare diseases\[[@ref9]\] and (ii) development of disease-specific knock-out mouse or animal models such as Japanese quail for Pompe disease and cat and dog for MPS type I.\[[@ref8]\]

###### 

Current globally marketed ERT products

  Disease                                Product           Company             US FDA\* approval/EU EMA^†^ approval   Treatment in India   Dose/frequency (IV infusion)   Approximate annual cost (INR) - 10 kg child
  -------------------------------------- ----------------- ------------------- -------------------------------------- -------------------- ------------------------------ ---------------------------------------------
  Gaucher                                Imiglucerase      Sanofi-Genzyme      1994/1997                              2002                 60 units/kg/EOW^‡^             40 lakhs
  Velaglucerase α                        Shire HGT         2010/2010           2014                                   60 units/kg/EOW      70 lakhs                       
  Taliglucerase α                        Protalix          2012/not approved   No information                         60 units/kg q EOW    No information                 
  Fabry                                  Agalsidase β      Sanofi-Genzyme      2003/2001                              2005                 1 mg/kg EOW                    20 lakhs
  Agalsidase α                           Shire HGT         Not approved/2001   2014                                   0.2 mg/kg EOW        20 lakhs                       
  Pompe                                  Alglucosidase α   Sanofi-Genzyme      2006/2006                              2008                 20 mg/kg EOW                   49 lakhs
  MPS§ I                                 Laronidase        Sanofi-Genzyme      2003/2003                              2006                 0.58 mg/kg weekly              46 lakhs
  MPS II                                 Idursulfase       Shire HGT           2006/2007                              2014                 0.5 mg/kg weekly               1 crore
  MPS IVA                                Elosulfase α      BioMarin            2014/2014                              No information       2 mg/kg weekly                 1.3crores
  MPS VI                                 Galsulfase        BioMarin            2005/2006                              2017                 1 mg/kg weekly                 1.1 crore
  MPS VII                                Vestronidase α    Ultragenyx          November 2017                          Not available        4 mg/kg EOW                    No information
  Lysosomal acid lipase deficiency       Sebelipase α      Alexion             2015/2015                              Not available        1-3 mg/kg weekly               3.2 crores
  Neuronal ceroidlipofuscinosis type 2   Cerliponase α     BioMarin            2017/2017                              Not available        300 mg EOW Intraventricular    4.7 crores

\*FDA: Food and drug administration, ^†^EMA: European Medicines Agency, ^‡^EOW: Every other week, ^§^MPS: Mucopolysaccharidosis

Enzyme Replacement Therapy in India {#sec1-1}
===================================

The first publication of ERT was from BARC Hospital, Mumbai, which described a 5-year-old boy who started receiving human placenta-derived alglucerase (Ceredase^®^) since 1999.\[[@ref10]\] Limited production of alglucerase because of limited availability of human placentae spurred the development of a DNA recombinant product analog of human β-glucocerebrosidase, imiglucerase.\[[@ref11]\] Subsequently in the year 2002, patients who were initially being treated with alglucerase were transitioned to imiglucerase therapy.

Procuring ERT in the early days was a lengthy process involving obtaining approval from manufacturer through charitable initiative, gathering documents including a prescription (countersigned by a doctor in government health service), certificate from the treating physician and a "P" license from the Directorate General of Health Services (DGHS), for import of drugs for personal use. Since the year 2015, patients can fill Form 12A online (SUGAM web portal, <https://cdscoonline.gov.in/CDSCO/Drugs_Personal>) to get the import license (Form 12-B) and obtain the custom duty exemption certificate from DGHS.

ERT for diseases other than Gaucher disease was introduced in India in the ensuing years \[[Table 1](#T1){ref-type="table"}\]. Of these products, imiglucerase, agalsidase β, laronidase, and alglucosidase α already have marketing authorization from DGHS, whereas application for registering velaglucerase α, agalsidase β, and idursulfase are in the process. Major centers having expertise in administering ERT are situated in Bengaluru (Indira Gandhi Institute of Child Health & Center for Human Genetics), Chennai (Fetal Care Research Foundation), Hyderabad (Rainbow Children\'s Hospital), Kochi (Amrita Institute of Medical Sciences), Lucknow (Sanjay Gandhi Postgraduate Institute of Medical Sciences), Mumbai (KEM Hospital and Jaslok Hospital), and New Delhi (AIIMS and Sir Ganga Ram Hospital). Indian patients access ERT through charitable initiatives of manufacturers and clinical trials. Few affected children of central and state government organization employees, namely, those working in armed forces, paramilitary forces, police, and government-owned public sector undertakings are now getting ERT as their expenses are being borne by these organizations. Three manufacturers are providing ERT through compassionate access programs in India: Sanofi-Genzyme through India Charitable Access Program (INCAP), Shire HGT\'s charitable access program in India in partnership with Direct Relief \[a non-governmental organization (NGO)\], and Protalix Therapeutics. In the year 2007, Sanofi-Genzyme constituted the Indian Medical Advisory Board (IMAB) whose board members are international physicians of repute, 10 local physicians from centers across India, and representatives of Sanofi-Genzyme to review applications for ERT made to INCAP, decide and prioritize eligibility for ERT, oversee ERT administration, and make recommendations for diagnostic evaluations and clinical monitoring of patients. Eligibility for ERT is decided by objective disease-specific inclusion and exclusion criteria based on published international guidelines and recommendations. Members of IMAB have recently published guidelines for ERT for Gaucher disease in India.\[[@ref12]\]

In the year 2011, Nagral *et al*. published preliminary experience of treating 25 patients of Gaucher disease with imiglucearse from five Indian centers.\[[@ref13]\] In eight patients treated for a mean period of 2.5 years, the hemoglobin increased by 2.2 g/dL, 50% had normal platelet count, and liver and spleen size decreased to one-third of the baseline size.\[[@ref13]\]

In 2017, 240 patients with LSDs received ERT through the initiative of various charitable organizations, namely, (i) the INCAP; 121 patients with LSDs---65 Gaucher disease, 20 MPS I, 13 Fabry disease, and 23 Pompe disease; (ii) Shire HGT\'s charitable access program; 69 patients with LSDs---35 Gaucher disease (including 7 who got velaglucerase α as post-trial access), 27 MPS II, and 7 Fabry disease; and (iii) Protalix; 5 patients with Gaucher disease received taliglucerase α. In addition, 43 children of central and state government organization employees received ERT.

From 2007 to 2012, a phase III clinical trial of velaglucerase α was conducted for patients with Gaucher disease at KEM Hospital, Pune, and AIIMS, New Delhi, allowing them free access to ERT.\[[@ref14]\]

Experience with Enzyme Replacement Therapy at KEM Hospital, Mumbai {#sec1-2}
==================================================================

Success stories {#sec2-1}
---------------

In 2001, alglucerase was started on a 7-year-old splenectomized girl with severe hematological, visceral, and skeletal manifestations of Gaucher disease requiring several packed cell and platelet transfusions. Subsequently, there was complete amelioration of all manifestations and she continues to be compliant and healthy on 11 years of therapy. Over the years, ERT has been initiated in 19 patients with LSDs, of which 12 continue to receive ERT \[[Table 2](#T2){ref-type="table"}\]. In our experience, hematological response has been timely and none of the patients subsequently required blood transfusion or splenectomy. However, these patients did not attain optimal therapeutic goals for reduction in hepatosplenomegaly, normalization of bone mineral density, and growth in the recommended time frame.\[[@ref15]\] Despite ERT, skeletal deformities (kyphoscoliosis and pectus carinatum) progressed in type III Gaucher disease. Nevertheless, ERT has transformed lives for several of these patients with Gaucher disease who are now able to pursue their academic ambitions, seek employment as professionals, and even get married \[[Table 2](#T2){ref-type="table"}\]. However, in a few patients we are encountering rare or unusual complications such as development of gaucheromas ("pseudotumors") which are a challenge to tackle.

###### 

Summary of ERT experience at KEM Hospital, Mumbai

  Patients                                                             Place of residence/distance (by road) from infusion center        Age         Interval: diagnosis & initiation of ERT   Duration of ERT (up to Dec 2017)   Outcome                                   
  -------------------------------------------------------------------- ----------------------------------------------------------------- ----------- ----------------------------------------- ---------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  1                                                                    Panvel, Maharashtra/\~ 40 kms                                     4 years     11 years 6 months                         7 years 6 months                   17 years 9 months                         MBA, working as an accountant
  2                                                                    Dombivali, Maharashtra/\~ 40 kms                                  5½ years    7 years 3 months                          21 months                          11 years (Eliglustat from January 2012)   2^nd^ year Masters (Commerce) student
  3                                                                    Solapur district, Maharashtra/\~ 380 kms                          20 months   33 months                                 13 months                          9 years 11 months                         7^th^ standard student
  4                                                                    Jalgaon district, Maharashtra/\~ 360 kms                          11½ years   11 years 9 months                         3 months                           4 years 9 months                          Discontinued ERT
  5                                                                    Mumbai                                                            10½ years   10½ years                                 Nil                                9 years 2 months                          2^nd^ year Bachelor (Engineering) student
  6                                                                    Mumbai                                                            15 years    15½ years                                 6 months                           7 years 11 months                         Graduate, MBBS
  7                                                                    Jamnagar, Gujarat/\~ 800 kms                                      37 months   39 months                                 2 months                           7 years 11 months                         5^th^ standard student
  8                                                                    Kolhapur district, Maharashtra/\~ 480 kms                         32 months   10 years 7 months                         7 years 11 months                  One dose                                  Expired due to disease related complications: Interstitial lung disease, hepatopulmonary syndrome and intracranial hemorrhage
  9                                                                    Navi Mumbai, Maharashtra/\~ 25 kms                                6 years     6½ years                                  6 months                           3 years 2 months                          Discontinued ERT
  10                                                                   Satara district, Maharashtra (migrated to Mumbai for treatment)   2 years     2 years 8 months                          8 months                           5 years                                   Junior KG (Interim 2 years of irregular treatment)
  11                                                                   Ulhasnagar, Maharashtra/\~ 50 kms                                 21 months   3½ years                                  21 months                          6 months                                  Not attending school
                                                                                                                                                                                                                                                                            
  **Gaucher disease: Neuronopathic (formerly type III)**                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                            
  1                                                                    Satara district, Maharashtra (migrated to Mumbai for treatment)   16 months   17 months                                 1 month                            8 years 11 months                         Repeating 3^rd^ year in 1^st^ standard, (Interim 2 years of irregular treatment)
  2                                                                    Sangli district, Maharashtra/\~ 390 kms                           18 months   37 months                                 19 months                          8 years 2 months                          5^th^ standard student
  3                                                                    Wardha, Maharashtra/\~ 730 kms                                    1 year      3 years 10 months                         2 years 10 months                  10 years 10 months                        7^th^ standard student
                                                                                                                                                                                                                                                                            
  **Hunter disease (Mucopolysaccharidosis type II)**                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                            
  1                                                                    Mumbai                                                            3½ years    5½ years                                  2 years                            38 months                                 2^nd^ standard student
                                                                                                                                                                                                                                                                            
  **Maroteaux-Lamy disease disease (Mucopolysaccharidosis type VI)**                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                            
  1                                                                    Mumbai                                                            4 years     8½ years                                  4½ years                           1 month                                   3^rd^ standard student
                                                                                                                                                                                                                                                                            
  **Pompe disease (classical, infantile)**                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                            
  1                                                                    Mumbai                                                            4 months    7½ months                                 3½ months                          3½ months                                 Expired
  2                                                                    Mumbai                                                            7 months    9 months                                  2 months                           2 months                                  Expired
  3                                                                    Navi Mumbai, Maharashtra/\~ 25 kms                                3 months    5 months                                  2 months                           2 months                                  Discontinued ERT, No follow up
  4                                                                    Dombivali, Maharashtra/\~ 40 kms                                  3 months    7 months                                  4 months                           20 months                                 Expired 4 months after ERT was discontinued

Enzyme replacement therapy\'s flip side {#sec2-2}
---------------------------------------

Because ERT needs to be administered as weekly or alternate weekly intravenous infusions, this involves daycare hospital admission. Life-long ERT therapy is definitely intrusive.\[[@ref7]\] In addition, several are outstation patients \[[Table 2](#T2){ref-type="table"}\] and their visits entail significant travel expenses, school and work absenteeism, and loss of wages for parents. Often these factors contribute to poor compliance. Hence after establishing disease control, we encourage patients to receive their ERT infusions in their hometown. Unfortunately, this outsourcing of ERT treatment has at times led to sub-optimal monitoring and undetected co-morbidities such as anemia and vitamin D deficiency. We also encountered difficulty in maintaining stringent temperature control (2°C--8°C) while transporting ERT vials to remote villages, which was often further compounded because of their erratic electricity supply. Because of this logistic limitation, we have had to discontinue outsourcing ERT infusions for a few patients. Two patients dropped out because of family problems. One adult patient with a LSD on ERT had to abandon traveling abroad for higher studies because of inability to continue receiving ERT through compassionate access outside India.

Patients with LSDs have to receive ERT life-long. As ERT does not cross the blood--brain barrier, it does not reverse central nervous system (CNS) abnormalities.\[[@ref8]\] In addition, it is less efficient in ameliorating manifestations in bones, cartilage, lymphnodes, skeletal muscles, cornea, heart valves, and lungs.\[[@ref7][@ref8]\] Established organ damage, namely, bone or visceral infarcts in Gaucher disease, and chronic kidney disease or strokes in Fabry disease do not reverse with ERT.\[[@ref6][@ref8]\] In classical Pompe disease, symptoms of cardiorespiratory insufficiency develop in the first few months after birth and these patients become ventilator-dependent and succumb by 1 year of age.\[[@ref16]\] Hence, timely diagnosis and initiation of ERT in these conditions is vital.

In European countries and in the United States, ERT is easily available to all afflicted individuals either through their National Health Services or through health insurance.\[[@ref17][@ref18]\] Improved awareness about LSDs among Indian doctors, availability of diagnostic tests, and setting up of treating centers has resulted in increased numbers of patients with LSDs being diagnosed. However, in our country procuring ERT to treat all diagnosed patients is currently not possible because of its prohibitive cost \[[Table 1](#T1){ref-type="table"}\]. Because our health insurance policies do not cover for LSDs, only a few patients get access to ERT. Charitable LSDs programs (mentioned earlier) can recruit only a few patients annually as per their prioritization policies. At our center, only 12, of the 37, confirmed patients with Gaucher disease could get access to ERT.\[[@ref15]\]

Overcoming challenges of enzyme replacement therapy {#sec2-3}
---------------------------------------------------

Development of IgG antibodies that reduce efficacy during ERT is a known phenomenon.\[[@ref19]\] This is least frequent with velaglucerase α and highest with alglucosidase α.\[[@ref8]\] High frequency of antibody response in patients with Pompe disease receiving alglucosidase α is attributed to their cross-reacting immunologic material (CRIM) status.\[[@ref8][@ref20]\] In CRIM-negative patients with Pompe disease, their immune system perceives the ERT protein as foreign resulting in production of sustained high antibody titers to alglucosidase α which mandates prophylactic immunomodulation (with rituximab, methotrexate, and intravenous immunoglobulin) to abrogate the immune response.\[[@ref8][@ref20]\]

In contrast to Gaucher disease and Hunter disease, treating classical Pompe disease with ERT at our center has been disappointing \[[Table 2](#T2){ref-type="table"}\]. Mortality has been 100% in classical Pompe disease in spite of ERT, probably a consequence of initiating treatment late or because of innate disease severity. Another reason for poor response to ERT could have been undetected CRIM-negative status in our cohort of patients with classical Pompe disease. Consequentially, now genotype is obtained in every patient with Pompe disease to predict CRIM status.\[[@ref8][@ref20]\] Two infants having Pompe disease were approved for ERT through INCAP; however, parents declined treatment probably because of complexity and life-long commitment of therapy.

ERT infusions require close clinical monitoring to preempt allergic reactions (including anaphylaxis). In patients receiving galsulfase and idursulfase, we use low-protein-binding 0.2 μm in-line filters for infusion along with premedication (antihistamine) administered 30 min before infusion. Apart from occasional mild febrile reactions with imiglucerase and idursulfase infusions, we have not observed any other adverse events.

The promise of easy enzyme replacement therapy access in India: What the future holds? {#sec2-4}
--------------------------------------------------------------------------------------

In recent years, individual patients and the "Lysosomal Storage Disorders Support Society of India" (LSDSS, a patient advocacy group) have filed writ petitions in the Honorable High Courts in New Delhi, Bengaluru, Chennai, and Hyderabad to direct the government to provide ERT free of cost to patients with LSDs. As an outcome of these litigations, ERT is now being funded for a few patients by the Employee State Insurance Corporation and by the State Government of Karnataka. The landmark judgment in the Mohammed Ahmed *versus* Union of India case \[W.P. (C) 7279/2013\] (<http://www.delhihighcourt.nic.in/dhc_case_status_oj_list.asp?pno=685222>) has led to the Union Ministry of Health and Family Welfare to recently draft the National Policy for Treatment of Rare Diseases.\[[@ref21]\] Two initiatives already taken include (i) creating a corpus fund of INR 100 crores for funding treatment of rare diseases (including LSDs) and (ii) development of a web-based online portal for applications for treatment funding. Patients can now email their application for funding to \<publichealth2\@yahoo.com\> the Section Officer, Rare Disease Cell, Ministry of Health & Family Welfare. Long-term goals for rare diseases include to (i) establish national registries and conduct epidemiologic studies to know their prevalence, (ii) facilitate research to improve diagnostic modalities, (iii) encourage indigenous drug companies to manufacture therapeutic drugs, and (iv) measures for price control including waiving import duty for ERT.

In conclusion, although LSDs are individually rare, several are currently treatable. ERT is currently the standard of care for selected LSDs and proceeds in parallel with supportive multidisciplinary medical and surgical interventions. The foremost prerequisite is a confirmed diagnosis. Early diagnosis is the key for optimum outcome. Although cost of ERT is exorbitant, there are avenues to access ERT in India. Government funding of ERT in India is anticipated to be introduced in a phased manner for selected ERTs in the near future.
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